Search

Regeneron Pharmaceuticals Inc

Closed

SectorHealthcare

836.16 1.44

Overview

Share price change

24h

Current

Min

820.99

Max

833.82

Key metrics

By Trading Economics

Income

570M

1.3B

Sales

685M

4.3B

P/E

Sector Avg

19.88

57.371

EPS

12.53

Dividend yield

0.45

Profit margin

30.226

Employees

15,410

EBITDA

695M

1.7B

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+1.05% upside

Dividends

By Acuity

Dividend yield

Sector Avg

0.45%

2.23%

Next Earnings

27 Oct 2026

Next Dividend date

31 Aug 2026

Market Stats

By TradingEconomics

Market Cap

13B

83B

Previous open

834.72

Previous close

836.16

News Sentiment

By Acuity

22%

78%

60 / 340 Healthcare

Regeneron Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

24 Aug 2026, 23:36 UTC

Regeneron Pharmaceuticals shares are slightly higher in after-market hours, reaching a high of 1.09% above Monday's close. No specific news was identified for the move.

21 Aug 2026, 23:46 UTC

Regeneron Pharmaceuticals Inc is trading lower in after-market hours, reflecting a slight decline since Friday's close, with no specific news identified.

20 Aug 2026, 23:26 UTC

Regeneron Pharmaceuticals Inc shares are higher in after-market trading, maintaining a strong position above the 20-day moving average and near the one-month range.

19 Aug 2026, 20:02 UTC

Social Media
Correlated Moves
News

Regeneron Pharmaceuticals gained FDA approval for Pasatru, a treatment for a rare genetic disorder. Shares are advancing, reflecting strong investor sentiment.

13 Aug 2026, 19:16 UTC

News
Social Media

Regeneron Pharmaceuticals is trading higher as social media highlights REGN17235's potential in ongoing clinical trials, supporting strong performance since Wednesday's close.

12 Aug 2026, 23:01 UTC

News

Regeneron Pharmaceuticals faces a securities fraud lawsuit over misleading statements regarding its Phase III Fianlimab-Libtayo Study, contributing to lower after-market trading.

11 Aug 2026, 23:01 UTC

Regeneron Pharmaceuticals shares are modestly higher in after-market hours. No specific company news was identified to explain this movement.

10 Aug 2026, 20:02 UTC

Regeneron Pharmaceuticals Inc shares are higher, supported by broader market strength and reduced expectations for Federal Reserve interest rate hikes following Friday's jobs report.

7 Aug 2026, 22:16 UTC

News

Regeneron Pharmaceuticals shares are lower in after-market hours following a class action lawsuit alleging securities fraud and unlawful business practices.

6 Aug 2026, 19:26 UTC

News
Social Media

Regeneron Pharmaceuticals faces a potential class action lawsuit over alleged securities fraud, contributing to a decline in shares despite receiving Health Canada approval for Libtayo.

5 Aug 2026, 20:06 UTC

Regeneron Pharmaceuticals is trading higher, reflecting gains since Tuesday, amid a decline in crude oil prices that eases inflationary pressures.

4 Aug 2026, 23:46 UTC

Regeneron Pharmaceuticals is roughly flat in after-market trading, remaining well above its 20-day moving average and near the upper end of its one-month range.

3 Aug 2026, 19:46 UTC

News

Regeneron Pharmaceuticals faces class action lawsuits over alleged securities fraud related to its Phase III Fianlimab-Libtayo Study, contributing to lower share prices.

1 Aug 2026, 00:01 UTC

News

Regeneron Pharmaceuticals shares are lower in after-market hours following a class action lawsuit alleging securities fraud and concerns over a failed clinical trial.

31 Jul 2026, 23:06 UTC

News

Regeneron Pharmaceuticals shares declined in after-market hours following a class action lawsuit alleging securities fraud related to its Phase III study modifications.

30 Jul 2026, 19:49 UTC

Regeneron Pharmaceuticals is trading higher, significantly above its 20-day moving average and near the upper end of its one-month trading range.

29 Jul 2026, 23:16 UTC

Regeneron Pharmaceuticals shares are higher in after-market trading, maintaining strength above the 20-day moving average despite broader market caution over rising interest rates.

28 Jul 2026, 23:06 UTC

Regeneron Pharmaceuticals Inc is higher in after-hours trading, continuing its positive momentum and remaining above its 20-day moving average. No specific news was identified.

27 Jul 2026, 23:51 UTC

Regeneron Pharmaceuticals shares are higher in after-market trading, maintaining momentum with strong cumulative returns and three consecutive higher daily closes.

25 Jul 2026, 00:02 UTC

Regeneron Pharmaceuticals shares are higher in after-market trading, reaching the upper end of their one-month trading range. No specific news was identified.

24 Jul 2026, 20:13 UTC

Regeneron Pharmaceuticals Inc shares are higher in after-market trading, remaining near the upper end of their one-month range. No specific news was identified.

23 Jul 2026, 09:56 UTC

Regeneron Pharmaceuticals Inc shares are modestly higher in pre-market trading. No specific company news was identified to explain the price movement.

22 Jul 2026, 23:46 UTC

Regeneron Pharmaceuticals shares are higher in after-hours trading, peaking post-market despite cautious sentiment from rising crude oil prices and geopolitical tensions.

21 Jul 2026, 23:51 UTC

News

Regeneron Pharmaceuticals faces a class action lawsuit for securities fraud over misleading claims about Fianlimab-Libtayo trial results. Shares are lower in after-hours trading.

17 Jul 2026, 19:26 UTC

Social Media
News

Regeneron Pharmaceuticals faces a class action lawsuit from Levi & Korsinsky, LLP, contributing to ongoing declines in the stock amid market volatility.

16 Jul 2026, 20:03 UTC

Regeneron Pharmaceuticals is trading higher, supported by gains in the Biotechnology sub-sector amid a strong broader market performance today.

15 Jul 2026, 19:16 UTC

Regeneron Pharmaceuticals Inc shares are higher Wednesday, recovering from an earlier dip and remaining above the 20-day moving average. No specific news was identified.

13 Jul 2026, 19:26 UTC

Regeneron Pharmaceuticals shares are lower today amid broader market declines driven by rising oil prices and geopolitical tensions. No specific company news was identified.

11 Jul 2026, 00:01 UTC

Regeneron Pharmaceuticals shares are higher in after-market trading, reflecting a notable gain near the upper end of its one-month trading range.

10 Jul 2026, 19:26 UTC

Correlated Moves

Regeneron Pharmaceuticals Inc shares declined amid broader biotechnology sector pressures and geopolitical tensions, despite earlier reaching a session high before pulling back.

Peer Comparison

Price change

Regeneron Pharmaceuticals Inc Forecast

Price Target

By TipRanks

1.05% upside

12 Months Forecast

Average 837.16 USD  1.05%

High 1,030 USD

Low 737 USD

Based on 19 Wall Street analysts offering 12 month price targets forRegeneron Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

19 ratings

12

Buy

7

Hold

0

Sell

Sentiment

By Acuity

60 / 340 Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
help-icon Live chat